Literature DB >> 23239537

Hepatitis B virus X protein (HBx)-related long noncoding RNA (lncRNA) down-regulated expression by HBx (Dreh) inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin.

Jin-feng Huang1, Ying-jun Guo, Chen-xi Zhao, Sheng-xian Yuan, Yue Wang, Guan-nan Tang, Wei-ping Zhou, Shu-han Sun.   

Abstract

UNLABELLED: The hepatitis B virus X protein (HBx) has been implicated as an oncogene in both epigenetic modifications and genetic regulation during hepatocarcinogenesis, but the underlying mechanisms are not entirely clear. Long noncoding RNAs (lncRNAs), which regulate gene expression with little or no protein-coding capacity, are involved in diverse biological processes and in carcinogenesis. We asked whether HBx could promote hepatocellular carcinoma (HCC) by regulating the expression of lncRNAs. In this study we investigated the alteration in expression of lncRNAs induced by HBx using microarrays and real-time quantitative polymerase chain reaction (PCR). Our results indicate that HBx transgenic mice have a specific profile of liver lncRNAs compared with wildtype mice. We identified an lncRNA, down-regulated expression by HBx (termed lncRNA-Dreh), which can inhibit HCC growth and metastasis in vitro and in vivo, act as a tumor suppressor in the development of hepatitis B virus (HBV)-HCC. LncRNA-Dreh could combine with the intermediate filament protein vimentin and repress its expression, and thus further change the normal cytoskeleton structure to inhibit tumor metastasis. We also identified a human ortholog RNA of Dreh (hDREH) and found that its expression level was frequently down-regulated in HBV-related HCC tissues in comparison with the adjacent noncancerous hepatic tissues, and its decrement significantly correlated with poor survival of HCC patients.
CONCLUSION: These findings support a role of lncRNA-Dreh in tumor suppression and survival prediction in HCC patients. This discovery contributes to a better understanding of the importance of the deregulated lncRNAs by HBx in HCC and provides a rationale for the potential development of lncRNA-based targeted approaches for the treatment of HBV-related HCC.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23239537     DOI: 10.1002/hep.26195

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  156 in total

Review 1.  Non-coding RNAs in hepatocellular carcinoma: molecular functions and pathological implications.

Authors:  Chun-Ming Wong; Felice Ho-Ching Tsang; Irene Oi-Lin Ng
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2018-01-10       Impact factor: 46.802

Review 2.  Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy.

Authors:  Renumathy Dhanasekaran; Jean-Charles Nault; Lewis R Roberts; Jessica Zucman-Rossi
Journal:  Gastroenterology       Date:  2018-11-04       Impact factor: 22.682

3.  Invasion and metastasis-related long noncoding RNA expression profiles in hepatocellular carcinoma.

Authors:  Yunzhen Gao; Geng Chen; Yongyi Zeng; Jinhua Zeng; Minjie Lin; Xiaolong Liu; Jingfeng Liu
Journal:  Tumour Biol       Date:  2015-04-22

4.  Long non-coding RNAs and hepatocellular carcinoma.

Authors:  Fu-Jun Yu; Jian-Jian Zheng; Pei-Hong Dong; Xiao-Ming Fan
Journal:  Mol Clin Oncol       Date:  2014-09-25

5.  Enhanced expression of long noncoding RNA CARLo-5 is associated with the development of gastric cancer.

Authors:  Yan Zhang; Mingzhe Ma; Weiyong Liu; Wenping Ding; Honggang Yu
Journal:  Int J Clin Exp Pathol       Date:  2014-12-01

6.  CCAT1 promotes hepatocellular carcinoma cell proliferation and invasion.

Authors:  Huaqiang Zhu; Xu Zhou; Hong Chang; Hongguang Li; Fangfeng Liu; Chaoqun Ma; Jun Lu
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

Review 7.  Long Non-coding RNAs and their Role in Metastasis.

Authors:  Ulrich H Weidle; Fabian Birzele; Gwen Kollmorgen; Rüdiger Rüger
Journal:  Cancer Genomics Proteomics       Date:  2017 May-Jun       Impact factor: 4.069

8.  LINC00152 promotes cell cycle progression in hepatocellular carcinoma via miR-193a/b-3p/CCND1 axis.

Authors:  Pei Ma; Haitao Wang; Jiangyang Sun; Hongzhou Liu; Chao Zheng; Xin Zhou; Zhongxin Lu
Journal:  Cell Cycle       Date:  2018-06-23       Impact factor: 4.534

9.  Genome-wide screening identifies oncofetal lncRNA Ptn-dt promoting the proliferation of hepatocellular carcinoma cells by regulating the Ptn receptor.

Authors:  Jin-Feng Huang; Hong-Yue Jiang; Hui Cai; Yan Liu; Yi-Qing Zhu; Sha-Sha Lin; Ting-Ting Hu; Tian-Tian Wang; Wen-Jun Yang; Bang Xiao; Shu-Han Sun; Li-Ye Ma; Hui-Rong Yin; Fang Wang
Journal:  Oncogene       Date:  2019-01-14       Impact factor: 9.867

10.  Upregulated GAPLINC predicts a poor prognosis in bladder cancer patients and promotes tumor proliferation and invasion.

Authors:  Zaosong Zheng; Dingjun Zhu; Fengjin Zhao; Jinli Han; Haicheng Chen; Yuhong Cai; Wenlian Xie
Journal:  Oncol Lett       Date:  2018-03-02       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.